stockrow
Friday 6 November 2026
Export XERS’s income statement to Excel — free account
Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
15.16
2.08
+15.90%
Follow XERS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
2,065.79 | 78.59 | 0.00 | 0.00 |
P/S ratio |
4.32 | 3.14 | 4.08 | 4.70 | |
P/FCF ratio |
45.09 | 20.81 | 24.59 | 23.79 | |
P/Operating CF |
62.83 | 100.21 | 165.65 | 48.77 | |
P/B ratio |
92.00 | 76.02 | 0.00 | 35.46 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.73 | 3.53 | 4.47 | 5.03 | |
EV/EBITDA |
33.70 | 21.32 | 28.35 | 35.01 | |
EV/Operating CF |
48.23 | 22.88 | 26.49 | 25.15 | |
EV/FCF |
49.43 | 23.37 | 26.94 | 25.47 | |
Quick Ratio |
1.48 | 1.42 | 0.95 | 1.48 | |
Current Ratio |
2.19 | 2.12 | 1.45 | 2.15 | |
Net Debt/EBITDA |
5.25 | 9.11 | 14.08 | 0.00 | |
Debt/Assets |
57.45% | 56.43% | 61.32% | 44.83% | |
Debt/Equity |
16.10 | 17.00 | (25.95) | 3.89 | |
Asset Turnover |
0.83 | 0.89 | 0.90 | 0.93 | |
Operating CF/Net income |
1.81 | 4.42 | (0.27) | 3.14 | |
Capex/Depreciation |
(0.08) | (0.08) | (0.05) | — | |
Interest Coverage |
2.34 | 1.15 | 0.74 | 2.62 | |
Research and Development Expense of Revenue |
9.18% | 10.57% | 11.58% | 10.31% | |
Selling, General and Administrative Expense of Revenue |
55.36% | 63.93% | 66.27% | 59.79% | |
Intangible Assets out of Total Assets |
0.29 | 0.28 | 0.26 | 0.24 | |
Share Based Compensation of Revenue |
6.14% | 4.98% | 12.02% | 10.07% | |
Graham Net Nets |
(0.10) | (0.13) | (0.11) | (0.05) | |
Graham Number |
0.09 | 0.36 | 0.35 | 0.00 | |
Earnings Yield |
0.05% | 1.27% | (1.21%) | (0.42%) | |
Free Cash Flow Yield |
2.22% | 4.80% | 4.07% | 4.20% | |
Revenue per Share |
0.53 | 0.49 | 0.53 | 0.59 | |
Operating CF per Share |
0.12 | 0.06 | 0.05 | 0.20 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.12 | 0.06 | 0.05 | 0.20 | |
Cash per Share |
0.69 | 0.66 | 0.70 | 0.72 | |
Shareholders Equity per Share |
0.09 | 0.08 | (0.06) | 0.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.09 | 0.08 | (0.06) | 0.27 | |
Free Cash Flow |
19.71 | 9.55 | 8.05 | 35.47 | |
Working Capital |
130.74 | 133.09 | 85.19 | 154.79 | |
Capital Expenditures |
(0.33) | (0.32) | (0.21) | — | |
Net Current Asset Value |
(129.52) | (127.32) | (146.88) | (85.17) | |
EV/EBIT |
55.45 | 30.93 | 40.98 | 39.59 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
50.58 | 27.55 | 37.40 | 36.98 | |
| Other line items | |||||
Average Receivables |
45.73 | 51.31 | 55.58 | 61.17 | |
Average Payables |
2.68 | 8.91 | 9.40 | 7.28 | |
Average Inventory |
58.42 | 63.46 | 74.11 | 72.19 | |
Average Assets |
353.29 | 353.73 | 373.30 | 396.71 | |
Average Common Equity |
(7.96) | (11.06) | (14.52) | 23.96 |
Columns are period end dates · fundamentals updated 5 Nov 2026